Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Clofarabine, Idarubicin, Cytarabine, Vincristine, and Corticosteroids for Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia

NCT02135874 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT02135874
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02135874 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Clofarabine, Idarubicin, Cytarabine, Vincristine, and Corticosteroids for Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 2
Overall status
Completed
Start date
October 27, 2014
Completion date
February 21, 2023
Enrollment
16 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute bilineal leukemia, acute biphenotypic leukemia, acute leukemia of ambiguous lineage, acute undifferentiated leukemia, mixed phenotype acute leukemia, mixed phenotype acute leukemia, b/myeloid, not otherwise specified, mixed phenotype acute leukemia, t/myeloid, not otherwise specified, recurrent mixed phenotype acute leukemia